Prognosis in drug-resistant epilepsy: seizure freedom, meaningful improvement and long-term review

Can treatment still make life substantially better? That question deserves a more careful answer than a single success rate. A patient may hope for complete seizure freedom, fewer injuries and emergency visits, or improved alertness alongside better control. Different interventions can affect those outcomes differently. Discussing prognosis means identifying the outcome that matters, the time over which it is measured and the possible costs to function or well-being. ILAE: Drug-Resistant Epilepsy, definition and clinical resourcesBaxendale et al.: ILAE neuropsychological assessment in epilepsy surgery, 2019

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Drug-resistant epilepsy describes failure to obtain sustained seizure freedom with appropriate, adequately used and tolerated medication schedules. It signals the need to reconsider the treatment pathway. It does not establish that every further option will fail. Cause, seizure type, previous treatment experience and the possibility of identifying a safely treatable target all influence what may be achievable. Timely comprehensive referral is appropriate once drug resistance is recognized. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022
A prospective study published in July 2026 in adults with drug-resistant focal epilepsy found that seizure freedom was associated with improvement across quality-of-life domains, while persistent depression was associated with worse outcomes. It did not establish that one specific medication is best for everyone. It supports including emotional health in the treatment review rather than treating it as separate from the outcome. Mula et al.: Drug-treatment changes, depression and quality of life in adult drug-resistant focal epilepsy, Epilepsia July 2026
Agree which events to record, over what period and alongside which everyday goals. Bring comparable information to successive appointments. Describe uncertain events honestly, with video or further monitoring when appropriate, instead of omitting them to demonstrate success or counting every unpleasant symptom as a seizure. Coexisting functional events, when present, need their own assessment and care. Tatum et al.: ILAE/IFCN minimum standards for inpatient long-term video-EEG, Epilepsia 2022 AAN: Management of Functional Seizures, clinical guideline summary, December 2025

Quick answer

Can treatment still make life substantially better? That question deserves a more careful answer than a single success rate. A patient may hope for complete seizure freedom, fewer injuries and emergency visits, or improved alertness alongside better control. Different interventions can affect those outcomes differently. Discussing prognosis means identifying the outcome that matters, the time over which it is measured and the possible costs to function or well-being. ILAE: Drug-Resistant Epilepsy, definition and clinical resources Baxendale et al.: ILAE neuropsychological assessment in epilepsy surgery, 2019

Full guide

Can treatment still make life substantially better? That question deserves a more careful answer than a single success rate. A patient may hope for complete seizure freedom, fewer injuries and emergency visits, or improved alertness alongside better control. Different interventions can affect those outcomes differently. Discussing prognosis means identifying the outcome that matters, the time over which it is measured and the possible costs to function or well-being. ILAE: Drug-Resistant Epilepsy, definition and clinical resources Baxendale et al.: ILAE neuropsychological assessment in epilepsy surgery, 2019

Drug resistance does not mean that improvement is impossible

Drug-resistant epilepsy describes failure to obtain sustained seizure freedom with appropriate, adequately used and tolerated medication schedules. It signals the need to reconsider the treatment pathway. It does not establish that every further option will fail. Cause, seizure type, previous treatment experience and the possibility of identifying a safely treatable target all influence what may be achievable. Timely comprehensive referral is appropriate once drug resistance is recognized. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

Prospective long-term observation has shown that some people with drug-resistant epilepsy later enter remission, while relapse can occur after a period of control. This supports continued purposeful care rather than a promise that waiting alone will solve the problem. A historical cohort's probability also cannot be treated as the personal forecast for someone beginning a particular contemporary treatment. Remission and relapse in a drug-resistant epilepsy population followed prospectively, Epilepsia 2011

Check what a study means by seizure freedom

Studies may distinguish freedom from disabling seizures from complete freedom from every seizure and aura. In the ILAE postoperative outcome classification, class 1 means complete seizure freedom without auras, whereas class 2 allows auras alone. A report combining those categories should not be described as showing that everyone achieved the strictest definition of complete freedom. Wieser et al.: ILAE classification of outcome following epilepsy surgery, 2001

Patients should continue to report brief familiar sensations or events even if they no longer involve a fall or convulsion. The treating clinician can assess whether a sudden sensation, fear, movement or other experience represents a seizure. Removing less dramatic events from a diary can make treatment appear more successful while obscuring information needed for safe follow-up.

Understand the difference between a responder rate and a median reduction

A responder rate counts the proportion of participants crossing a specified improvement threshold, often a reduction of at least half in the measured seizure frequency. A median percentage reduction describes the middle of the distribution of changes. Neither means that the same percentage of patients became seizure-free, and neither predicts the result that each participant experienced. Nair et al.: Nine-year prospective brain-responsive neurostimulation outcomes, Neurology 2020 Manral et al.: Modified Atkins diet randomized trial in adolescent and adult DRE, Neurology 2023

Residual events also matter. Two people with the same relative reduction can have very different remaining burdens if one still has sudden injurious falls while the other mainly has brief less disruptive episodes. Ask about severity, recovery time, rescue medication and injuries as well as total frequency. A treatment can offer valuable partial improvement without satisfying the patient's ultimate goal.

Match the observation period to the claim

Several quiet weeks, a full year without seizures and many years of continuous control convey different levels of information. Someone whose untreated events were already widely spaced needs an observation period that takes that history into account. A short favorable interval should not be selected and presented as proof of durable success. Both research definitions and individual reviews require an appropriate time context. NICE NG217: Terms used, drug-resistant epilepsy definition, updated January 2025 NICE NG217: Principles of treatment, safety, monitoring and withdrawal

Agree when early response will be assessed, when sustained benefit can reasonably be evaluated and which changes justify contact before the next appointment. An initial response can evolve as medication is adjusted, a device is programmed or recovery progresses. Prognosis is therefore a judgment updated with evidence, not a permanent statement made at the first prescription or discharge.

Do not rank unlike studies by their headline numbers

Medication trials and surgical series often enroll different populations. A surgical study may require prior evidence that a target can be treated with acceptable risk; a drug study may include people with a different number of previous failures and different seizure burdens. Even a shared phrase such as seizure freedom does not make the results directly comparable when eligibility, follow-up and analysis differ. Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26 Wiebe et al.: Randomized trial of surgery for temporal-lobe epilepsy, NEJM 2001

The randomized temporal-lobe surgery evidence and the early-surgery ERSET trial support consideration of surgery in appropriately selected patients. They do not show that every drug-resistant epilepsy should be treated with resection. Individual language, memory and other functional risks remain part of the decision. Ask the clinician to explain where you resemble the study population and where the comparison becomes less reliable. Engel et al.: Early surgery versus medical treatment for drug-resistant MTLE, randomized trial, JAMA 2012 Baxendale et al.: ILAE neuropsychological assessment in epilepsy surgery, 2019

Long-term stimulation results need their study context

Responsive neurostimulation follow-up describes sustained seizure reductions and periods of seizure freedom in some participants. Its long-term phase was observational and open label. Deep brain stimulation follow-up likewise suggests that benefit can evolve over time, while medication and programming may change and the composition of the remaining follow-up group needs consideration. Nair et al.: Nine-year prospective brain-responsive neurostimulation outcomes, Neurology 2020 Salanova et al.: SANTE long-term thalamic stimulation study, Epilepsia 2021

These findings support ongoing assessment and adjustment; they do not promise immediate freedom from seizures after implantation. Clarify the intended outcome, the review schedule and what would count as an adequate treatment attempt before another strategy is considered. A functioning battery and intact hardware are important, but they do not by themselves establish that the clinical goal has been reached.

Include functional outcomes when considering ablation

Seizure results after ablation should be considered alongside memory, language, mood and other complications. The 2025 laser-treatment registry adds follow-up evidence in selected mesial temporal lobe epilepsy. Research on language after radiofrequency thermocoagulation also shows that a small treatment volume can still affect an important network. The size of the incision is not a complete measure of prognosis. Interstitial Thermal Therapy in Mesial Temporal Lobe Epilepsy, prospective LAANTERN registry, JAMA Neurology 2025 Cockle et al.: Language mapping and decline after SEEG radiofrequency thermocoagulation, Brain 2025

Documenting relevant abilities before treatment helps distinguish pre-existing difficulties from subsequent changes. A patient who finds ordinary conversation harder or can no longer perform a familiar task needs assessment even if seizures have decreased. Conversely, not every longstanding problem should automatically be attributed to the recent procedure. Careful comparison is more useful than either assumption.

Quality of life is not another name for seizure frequency

A prospective study published in July 2026 in adults with drug-resistant focal epilepsy found that seizure freedom was associated with improvement across quality-of-life domains, while persistent depression was associated with worse outcomes. It did not establish that one specific medication is best for everyone. It supports including emotional health in the treatment review rather than treating it as separate from the outcome. Mula et al.: Drug-treatment changes, depression and quality of life in adult drug-resistant focal epilepsy, Epilepsia July 2026

Ask about sleep, energy, confidence, memory and participation in ordinary life. A person may have fewer seizures but remain too sleepy to study or too frightened to leave home. Those concerns can require further treatment adjustments or support. Improvements do not necessarily happen in every area at the same time, and a favorable seizure diary should not close discussion of everything else that remains difficult.

State your priorities rather than assuming they are understood

A multinational survey published in 2026 identified differences among patients, caregivers and clinicians in treatment priorities and consultation topics. It was a cross-sectional questionnaire study, not a description of every Chinese family, but it illustrates why patients should be asked directly what they most want to change. Clinical priorities and personal priorities may overlap without being identical. Lattanzi et al.: Patient, caregiver and clinician treatment priorities in DRE, multinational survey, 2026

Before a review, the patient and caregiver can each write down their most important goal. Independent travel, fewer nocturnal events and less medication-related fatigue may lead to different discussions. The team can then explain how priorities will be balanced and when to revisit them. Explicitly acknowledging a difference is more productive than assuming that everyone has agreed on a goal they have never discussed.

Developmental outcomes need their own assessment

In developmental and epileptic encephalopathies, the underlying cause and epileptic activity can both contribute to developmental difficulties. Seizure control is valuable but cannot guarantee reversal of every existing problem. Prognosis must consider the child's abilities, cause, treatment history and available educational or rehabilitation support. Another child's progress is not a forecast for this child. ILAE: Introduction to the epilepsy syndrome position papers, 2022 Krey et al.: Current practice in diagnostic genetic testing of the epilepsies, ILAE Genetics Commission, 2022

Families can describe changes in communication, feeding, movement, learning and participation in daily routines. Reports from school or therapy can add a different view of the same period. If treatment affects alertness or tolerance of rehabilitation, bring that information to the epilepsy team. Developmental benefit cannot be judged solely by an isolated EEG description.

Risk reduction does not mean that all risk disappears

Continuing tonic-clonic seizures are relevant to epilepsy-related mortality risk, including SUDEP. Treatment, reliable medication use and individualized safety planning are important topics. The word drug-resistant cannot be converted into a personal countdown, and no monitoring device should be described as guaranteeing prevention. A risk discussion should identify practical measures and concerns relevant to the individual. NICE NG217: Reducing epilepsy-related death and SUDEP risk

The household needs to know how to protect the person during a seizure, time the event and activate the emergency plan. A prolonged or otherwise dangerous seizure requires timely help even after several months of good control. Review safety arrangements when treatment, living circumstances or supervision needs change. Focusing only on a numerical risk can distract from actions that the family can actually take. CDC: First Aid for Seizures

Good control is not automatic permission to stop medication

Medication reduction depends on the cause, previous course, type of treatment, duration of control and consequences of recurrence. Short-term seizure freedom does not justify abrupt discontinuation, including after surgery. Driving, swimming alone and hazardous work raise additional questions about personal safety and the rules that apply locally; each needs its own assessment. NICE NG217: Principles of treatment, safety, monitoring and withdrawal

If the wish to reduce medicine comes from fatigue, expense or unreliable supply, say so directly. These are meaningful issues that may be addressed without immediate withdrawal. An apparently stable regimen can become fragile when the practical burden is hidden. The goal is a plan the patient can maintain, rather than a favorable chart entry that overlooks an approaching interruption in treatment.

Ask a Chinese team how its outcome estimate applies to you

To discuss prognosis usefully, a receiving center in China needs the actual treatment history, representative event descriptions or videos, original imaging and relevant investigations. When research or local outcomes are quoted, ask about selection criteria, denominators, follow-up completeness and the way complications were counted. Experience with many procedures is relevant, but it does not replace those details. 中国抗癫痫协会官方网站及CAAE癫痫地图入口 Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

A center managing more complex cases may have a different overall result from another center even when both provide careful care. Unadjusted success rates alone are therefore a poor basis for ranking services. For international treatment, also establish how medication, devices and functional outcomes will be reviewed after departure from China. Broken follow-up can affect both maintenance of benefit and the ability to judge it accurately.

Turn the next review into a comparison that can guide care

Agree which events to record, over what period and alongside which everyday goals. Bring comparable information to successive appointments. Describe uncertain events honestly, with video or further monitoring when appropriate, instead of omitting them to demonstrate success or counting every unpleasant symptom as a seizure. Coexisting functional events, when present, need their own assessment and care. Tatum et al.: ILAE/IFCN minimum standards for inpatient long-term video-EEG, Epilepsia 2022 AAN: Management of Functional Seizures, clinical guideline summary, December 2025

When a goal has not been reached, the response may involve clarifying the cause, adjusting treatment, completing an evaluation or reconsidering the order of priorities. When a worthwhile benefit has occurred, discuss how to preserve it and address the remaining burden. A useful prognosis conversation leaves the patient with a clear account of what has improved, what remains uncertain and what the next assessment will decide. NICE NG217: Principles of treatment, safety, monitoring and withdrawal Mula et al.: Drug-treatment changes, depression and quality of life in adult drug-resistant focal epilepsy, Epilepsia July 2026